A comparison of the Effects of Vytorin (Ezetimibe and Simvastatin) versus Lipitor (Atorvastatin) in inducing changes to levels of novel serum biomarkers associated with Coronary Heart Disease risk.

Next Previous
Trial Profile

A comparison of the Effects of Vytorin (Ezetimibe and Simvastatin) versus Lipitor (Atorvastatin) in inducing changes to levels of novel serum biomarkers associated with Coronary Heart Disease risk.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Pharmacodynamics
  • Acronyms VYTUL

    • Most Recent Events

    • 05 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top